Remiges Ventures

Remiges Ventures is a US-Japan cross-border life-sciences venture capital firm founded in 2014 with offices in Seattle, Washington and Tokyo, Japan. The firm invests in early-stage drug discovery and therapeutic development companies and is distinguished by deep connections to Japanese academic medical research and the Japanese pharmaceutical industry, giving portfolio companies strategic access to Japanese partnering, clinical development pathways, and licensing opportunities alongside US and global scale. Remiges is led by Founder, Managing Partner and Managing Director Taro Inaba and is a SEC-registered investment adviser. Remiges has raised two biopharma funds. Remiges BioPharma Fund II closed in April 2021 at a final $95 million and attracted a strategic LP base including Taiho Pharmaceutical, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, 1Globe Capital, EA Pharma, and Senju Pharmaceutical. The firm makes minority investments at seed, early-stage, and later-stage rounds, typically alongside strategic pharma syndicates. Alongside its investment activity, Remiges launched RDiscovery, a life-sciences incubator focused on advancing early-stage therapeutic concepts through company creation. The portfolio has expanded to 15 active companies. Notable investments include Glycomine (PMM2-CDG Phase 2 therapeutic, where Remiges led a Series C follow-on in April 2025), Restore Vision (Series A with first-in-human data in 2024), Eurus Therapeutics, Ride Health, KUPANDO, and Capacity Bio. The firm made 2 new investments in 2024 and at least 2 in 2025. Remiges occupies a distinct cross-border niche: its pharma LP base creates structural alignment between investor interests and portfolio company commercial development, while its Tokyo presence provides a genuine channel to Japanese clinical partnerships that pure US-based life-sciences funds cannot replicate.